Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended September 30, 2023, was approximately S$2,250,000, representing a decrease of approximately S$169,000 or 7.0% compared to S$2,419,000 for the same period in 2022[11]. - The unaudited loss for the Group was approximately S$3,921,000 for the nine months ended September 30, 2023, a decrease of approximately S$1,579,000 or 28.7% from a loss of S$5,500,000 for the same period in 2022[11]. - Loss per share for the Company was approximately 0.31 Singapore cents for the nine months ended September 30, 2023, compared to 0.47 Singapore cents for the same period in 2022[11]. - The total comprehensive expenses for the period amounted to S$3,790,000, compared to S$5,848,000 for the same period in 2022[12]. - The company reported a loss before taxation of S$3,921,000 for the nine months ended September 30, 2023, compared to a loss of S$5,500,000 in the same period of 2022, indicating an improvement of about 29%[104]. - The total comprehensive loss for the nine months ended September 30, 2022, was S$6,233,000, indicating a worsening financial position compared to the current period[14]. Revenue Breakdown - Dental services generated revenue of S$1,472,000 for the nine months ended September 30, 2023, with trading sales contributing S$778,000[89]. - Revenue from trading sales decreased significantly from S$2,419,000 in 2022 to S$778,000 in 2023, indicating a decline of approximately 68%[89]. - Revenue recognition for healthcare services is primarily at a point in time, with all S$2,250,000 recognized in this manner for the nine months ended September 30, 2023[89]. - The Group's revenue from aesthetic services is generally received upfront and recognized as deferred revenue, reflecting a stable cash flow model[74]. - Revenue from consultation services is typically recognized over a period of less than one day, indicating a quick turnaround in service delivery[75]. - Revenue from prescription and dispensing services is recognized at the point when the patient obtains control of the medication, ensuring timely revenue recognition[81]. Operating Expenses - Employee benefits expense decreased to S$2,011,000 for the nine months ended September 30, 2023, from S$2,396,000 in the same period in 2022[12]. - Other operating expenses decreased to S$2,639,000 for the nine months ended September 30, 2023, from S$2,910,000 for the same period in 2022[12]. - The Group's cost of consumables and medical supplies used was approximately S$1,000,000 for the nine months ended September 30, 2023, down from approximately S$1,099,000 in 2022[126][130]. - Other income increased significantly to S$952,000 in the nine months ended September 30, 2023, from S$48,000 in the same period of 2022[94]. - Finance costs decreased to S$48,000 for the nine months ended September 30, 2023, down from S$86,000 in the same period of 2022, reflecting a reduction of approximately 44%[95]. Corporate Governance - The company complied with all applicable code provisions of the Corporate Governance Code during the nine months ended September 30, 2023[172]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[171]. - The Audit Committee consists of three independent non-executive directors, ensuring compliance with GEM Listing Rules[196]. - The company has adopted a code of conduct for directors' securities transactions that meets or exceeds GEM Listing Rules standards[184]. - The company will continue to review and improve its corporate governance practices[171]. Shareholder Information - The company did not recommend the payment of any dividend for the nine months ended September 30, 2023[11]. - The weighted average number of ordinary shares in issue increased to 1,260,536,000 for the nine months ended September 30, 2023, from 1,174,599,000 in the same period of 2022[104]. - The total number of share options as of September 30, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[180]. - The company has adopted a share option scheme, granting a total of 60,000,000 share options to ten directors and eligible participants at an exercise price of HK$0.109 per share[177]. - The company did not purchase, sell, or redeem any of its listed securities during the nine months ended September 30, 2023[182]. Business Strategy - The Company plans to shift its core business operations to dental implant services, supported by a two-year business development plan established in 2022[114][118]. - The Company identifies a significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[115][115]. - The core business has transitioned from dermatology aesthetic services to dental care and dental implant services due to changes in the business environment[121][122]. - The Group will focus resources on the continuous development of dental services while maintaining a prudent investment strategy[116][116]. - The Group's operational performance will be closely monitored to maximize shareholder value[116][116].
德斯控股(08437) - 2023 Q4 - 季度业绩